Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proligliptin + metformin
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Proligliptin + metformin is a fixed-dose combination (FDC) therapy developed by CSPC Pharmaceutical Group for the management of type 2 diabetes mellitus. Proligliptin (DBPR108) is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, proligliptin enhances glucose-dependent insulin secretion and suppresses glucagon release. Metformin, a biguanide, complements this action by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I, leading to reduced hepatic gluconeogenesis and improved insulin sensitivity in peripheral tissues. This combination aims to provide superior glycemic control compared to monotherapy while simplifying the treatment regimen for patients.
- Other names
- proligliptin/metformin普格列汀二甲双胍
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on proligliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proligliptin + metformin.